Traws Pharma (TRAW) Share-based Compensation (2012 - 2026)
Traws Pharma (TRAW) posted quarterly Share-based Compensation of $2.1 million for Q1 2026, up 1189.44% year-over-year from $161000.0 in Q1 2025, and up 534.86% quarter-over-quarter from $327000.0 in Q4 2025.
Traws Pharma (TRAW) Share-based Compensation (2012 - 2026) Analysis & Trends
Traws Pharma (TRAW) has reported Share-based Compensation for 15 consecutive years, with $2.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation rose 1189.44% year-over-year to $2.1 million; the TTM figure through Mar 2026 stood at $2.1 million (up 70.44% YoY), while the FY2025 annual figure was $1.6 million, up 14.53% from the prior year.
- Share-based Compensation advanced to $2.1 million in Q1 2026 per TRAW's latest filing, from $327000.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $2.1 million in Q1 2026 and bottomed at $105000.0 in Q2 2025.
- Historically, Share-based Compensation has averaged $391235.3 across 5 years, with a median of $330000.0 in 2022.
- Annual changes were most pronounced in 2025 — Share-based Compensation sank 72.37% — and 2026, when it surged 1189.44%.
- Traws Pharma's Share-based Compensation stood at $330000.0 in 2022, then advanced by 0.61% to $332000.0 in 2023, then increased by 0.6% to $334000.0 in 2024, then fell by 2.1% to $327000.0 in 2025, then surged by 534.86% to $2.1 million in 2026.
- Business Quant data shows TRAW's Share-based Compensation at $2.1 million in Q1 2026, $327000.0 in Q4 2025, and $135000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Traws Pharma | 5.60 Mn | 588,417.40 | - | 816,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.08 Mn |
| Mar 31, 2026 | 2.08 Mn |
| Dec 31, 2025 | 327,000.00 |
| Dec 31, 2025 | 327,000.00 |
| Sep 30, 2025 | 135,000.00 |
| Sep 30, 2025 | 135,000.00 |
| Jun 30, 2025 | 105,000.00 |
| Jun 30, 2025 | 105,000.00 |
| Mar 31, 2025 | 161,000.00 |
| Mar 31, 2025 | 161,000.00 |
| Dec 31, 2024 | 334,000.00 |
| Dec 31, 2024 | 334,000.00 |
| Sep 30, 2024 | 343,000.00 |
| Sep 30, 2024 | 343,000.00 |
| Jun 30, 2024 | 380,000.00 |
| Jun 30, 2024 | 380,000.00 |
| Mar 31, 2024 | 333,000.00 |
| Mar 31, 2024 | 333,000.00 |
| Dec 31, 2023 | 332,000.00 |
| Dec 31, 2023 | 332,000.00 |